EXEL Falls After Colorectal Cancer Trial Misses Statistical Goals

Shares of Exelixis (EXEL) fell sharply in Wednesday trading after the company announced that its STELLAR-303 clinical trial for Zanzalintinib did not meet the required statistical significance in overall survival for a key subgroup of colorectal cancer patients. The results have raised investor concerns about the drug's regulatory approval prospects.

Trial Details

Data from the Phase 3 STELLAR-303 trial showed that Zanzalintinib failed to achieve the primary endpoint of improving overall survival in patients with metastatic colorectal cancer who had received prior therapy. Although the drug showed some activity in other subgroups, the overall result was below expectations.

Market Reaction

EXEL stock dropped over 15% in early trading, hitting its lowest level in several months. Trading volume more than doubled compared to the daily average, reflecting heightened investor anxiety.

Broader Context

Analysts had previously projected Zanzalintinib could generate up to $1 billion in annual sales if approved. With these disappointing results, Exelixis may need to reassess the drug's development program or explore other indications.

What This Means for Investors

Investors should watch for any updates from Exelixis regarding alternative plans for the drug or a shift in focus to its other pipeline assets. The stock may remain volatile until the regulatory path becomes clearer.